rj

[rj @sharpie510]

There is HOPE for #GBM patients, but you must advocate for yourself.

NO EVIDENCE OF DISEASE from a RECURRENT #GLIOBLASTOMA that was only partially resected! The remaining tumor vanished thanks to #DCVax-L.
💪

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

$nwbo

[Douglas Charles Duckworth 🇺🇸🇨🇱⚜️🏴‍☠️ @DCVaxDefender]

Huge SNO 2026 readout (CTIM-27), this Sunday November 15, from Moffitt Cancer Center's Dr Peter Forsyth, Dr Brian Czerniecki, and Dr Pawel Kalinski. Here is what this cancer is, why current treatments fail, and why this breakthrough matters enormously for both patients and $NWBO shareholders:

1. What is this cancer?

Leptomeningeal disease (LMD) occurs when breast cancer cells spread into the cerebrospinal fluid (CSF), the liquid surrounding the brain and spinal cord, and the thin protective membranes lining them. It frequently strikes younger women with aggressive subtypes such as HER2+ or triple-negative breast cancer (TNBC).

2. Why do standard treatments fail?

Most intravenous chemotherapy and targeted antibody drugs cannot cross the blood-brain barrier into the spinal fluid in high enough concentrations to clear tumour cells hiding there.

Spinal fluid naturally lacks trained killer T cells, and checkpoint inhibitors fail on their own because there are no properly instructed immune cells in the CSF for them to activate.

Once breast cancer reaches the spinal fluid, patients deteriorate rapidly, suffering severe headaches, nerve damage, and loss of mobility or vision, with historical median survival typically lasting just 2 to 6 months.

3. Why is this a major breakthrough for patients?

Rather than poisoning the body with toxic drugs, Moffitt's team took each patient's own immune cells, trained them outside the body into Type-1 polarised dendritic cells (cDC1s), and infused them directly into the spinal fluid.

The data is quite impressive:

16.24-month median overall survival across 15 heavily pre-treated, post-radiation patients (10 HER2+, 5 TNBC), so roughly three to four times longer than historical outcomes, with manageable side effects (mainly temporary headaches as the immune response kicked in for the patient.

In every single patient, immune cell counts in the spinal fluid surged (from a median of 4 to 179 cells, reaching up to 2,550), driven by spikes in natural immune messengers (IFN-γ and IL-12) that reversed T-cell exhaustion.

4. Why is this critical for shareholders?

Co-author Dr Pawel Kalinski is the pioneer behind αDC1 (alpha-type-1 polarised dendritic cell) biology.

He co-invented the joint Kalinski–Czerniecki αDC1 patent filing (US 2024/0299544) and invented the licensed University of Pittsburgh ST-αDC1 patent (US 12,059,434), which are part of the exact dendritic cell portfolio @NorthwestBio exclusively in-licensed from Roswell Park and UPitt for commercial development.

Big Pharma's checkpoint inhibitors fail in "cold" tumours because releasing the brakes on T cells achieves nothing if dendritic cells have not told them what to do in the patient.

Moffitt's Phase II trial now pairs these intrathecal dendritic cells directly with nivolumab or trastuzumab proving that ex vivo DC vaccines are the essential foundation that makes other cancer drugs work.

Academic centres can produce small batches for local trials, but commercialising personalised dendritic cell therapies at scale requires automated, closed-system manufacturing which is precisely what @NorthwestBio has built with its EDEN (Flaskworks) platform and Sawston facility.

They also hired the top DC manufacturing expert from Roswell Park obviously to support future trials and the commercialization of Northwest Biotherapeutics entire immunotherapy pipeline.

https://t.co/ibYzXwQLjD

Yet again it's now proven that Ex vivo DC instruction works while Big Pharma are clearly watching.

https://t.co/GypLIltqcg

https://t.co/H4QL35wDSK

https://t.co/0SDrNSEuRX

https://t.co/fnGqMez8gn

[Cancer Survivors @Ali_boy_180]

.
. ******* How personalised vaccines are changing the fight against brain cancer *****
.
. #DCVax #GBM #Glioblastoma #CancerFree
.
https://t.co/baZklDdwfZ

[d_stock @d_stock07734]

$NWBO

No other treatment has ever produced results like this, and that's DCVax-L combined with temozolomide alone. Now imagine what could happen when DCVax-L is combined with an upgraded version of Hiltonol, a PD-1 inhibitor, and a CSF1R inhibitor.

https://t.co/VxDWUGrn9G

[rj @sharpie510]

There is HOPE for #GBM patients, but you must advocate for yourself.

NO EVIDENCE OF DISEASE from a RECURRENT #GLIOBLASTOMA that was only partially resected! The remaining tumor vanished thanks to #DCVax-L.
💪

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

$nwbo

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

❤️🙏 ANOTHER MRI. ANOTHER ANSWERED PRAYER!

NO EVIDENCE OF DISEASE!!! 🎉❤️

Today, Braelyn had another brain MRI, and I am absolutely OVERJOYED to share that it once again showed NO EVIDENCE OF DISEASE!

NO CHANGE from her August MRI!

And just FOUR DAYS AGO, on Friday, November 6, Braelyn received her 5th DCVax-L treatment in London! 🇬🇧

I cannot begin to describe the emotions.

After more than three years of fighting this devastating brain cancer, three major brain tumor surgeries, radiation, countless treatments, and more fear than I ever imagined a mother could endure, we are now celebrating another MRI showing NO EVIDENCE OF DISEASE!

I wish I could tell you that the scanxiety gets easier. But it doesn’t. At least not for me.

Every MRI brings back the memories of devastating scans, heartbreaking news, and the terrifying uncertainty of what might come next.

I still find myself holding my breath, praying desperately for those words.

And today, we heard them again.

NO EVIDENCE OF DISEASE. ❤️🙏

My heart is overflowing with gratitude.

To every single person who has prayed for Braelyn, supported our family, donated to help make her treatments possible, shared her story, or simply sent us words of encouragement—THANK YOU!

You have helped carry us through the darkest days of our lives, and you are now helping us celebrate some of the brightest.

And to Northwest Biotherapeutics ($NWBO), the brilliant Dr. Linda Liau at UCLA, and the extraordinary Professor Keyoumars Ashkan at King’s College Hospital—there are simply no words adequate to express our gratitude.

Thank you for your dedication, your compassion, and your determination to bring new hope to patients facing this devastating disease.

Braelyn is 19 years old. She’s attending college. She’s dreaming about her future.

And today, once again, her MRI shows NO EVIDENCE OF DISEASE!

GOD IS GOOD! ❤️🙏

#DCVax #BrainCancer #BraelynsFight #NoEvidenceOfDisease
#DCvaxForBraelyn

[rj @sharpie510]

Fourteen years after being told he had little time left, he has built a life and career that once seemed impossible.

Jamil got DCVax-L for #glioblastoma. 14 years & cancer-free.
#gbm #dcvax $nwbo

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

https://t.co/b6A0rNrPJ2

[rj @sharpie510]

Fourteen years after being told he had little time left, he has built a life and career that once seemed impossible.

Jamil got DCVax-L for #glioblastoma. 14 years & cancer-free.
#gbm #dcvax $nwbo

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

https://t.co/b6A0rNrPJ2

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

I want to add some context to Braelyn’s MRI images that more than 145,000 people have now seen.

Because when you understand what was happening inside her brain only months ago, her latest MRI becomes even more remarkable.

The image on the left is Braelyn’s brain from February this year.

Her tumor had become enormous. When we first connected with Dr. Linda Liau at UCLA—with Thomas McCaffrey’s help—Braelyn already had an 11 mm midline shift from the pressure the tumor was creating.

Dr. Liau and the UCLA tumor board reviewed her MRI, and during our first Zoom appointment she told us:

Braelyn needed surgery. Immediately.

That may sound obvious looking at this image.

But before reaching UCLA, I had contacted surgeons in the Southeast desperately trying to find someone willing to operate on my daughter.

Three surgeons turned her down.

Her case was considered too complicated and too risky. The options being offered to us were chemotherapy and photon radiation.

And I was angry.

My daughter’s brain was being overtaken by an extraordinarily aggressive tumor, and I felt like everyone was giving up on her when what she desperately needed was someone willing to try.

By the time we made it to UCLA just a couple of weeks later, despite high-dose steroids, that 11 mm midline shift had progressed to 20 mm.

The pressure had become so extreme that her brain was starting to herniate outward through the opening from her previous craniectomy.

In a strange twist, that opening may have saved her life by providing somewhere for her swelling brain to go.

Now look at the image beside it.

That is Braelyn’s most recent MRI from August.

No giant mass.

No 20 mm shift.

And after reviewing the images, Dr. Liau and the UCLA tumor board told us they could see no tumor tissue—including the residual tumor that had intentionally been left behind during surgery because of its proximity to critical structures.

This is why her latest MRI means so much to us.

This wasn’t a small, slow-growing tumor.

We watched this monster create an 11 mm shift that progressed to 20 mm in a matter of weeks.

We know one MRI isn’t the end of this story. Braelyn will continue treatment, and we’ll keep watching every scan.

But I will never forget looking at that first MRI.

It took our breath away.

It was terrifying. It felt like being kicked in the gut. I looked at my daughter’s brain being pushed so dramatically to one side and wondered how we were going to get her through this.

And then, only months later, we looked at the MRI beside it.

That one took our breath away, too.

But for an entirely different reason - relief and gratitude.

Same daughter. Same brain. Two images I will never forget for completely different reasons.

When you understand where she was…

you understand why this MRI feels so extraordinary. ❤️🙏

And I will forever be grateful to the surgeon who looked at a case others considered too risky and said:

She needs surgery.

Thank you, Dr. Liau. ❤️
#DCvaxForBraelyn
$NWBO

[rj @sharpie510]

...Professor Keyoumars Ashkan who, while explaining the risks of surgery, claimed he could remove 50-70% of the tumour.

I hope she can then receive #DCVax-L for her #glioblastoma.
🙏

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

#gbm $nwbo

https://t.co/sd5NVF7mnV

[rj @sharpie510]

@FDA needs to make DCVax-L available to patients in the USA.

Why continue to deny this life-extending non-toxic cancer vaccine to patients that have no viable alternative?

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

#gbm #glioblastoma #dcvax $nwbo

[Al Musella @AlMusella]

Our comment to the FDA has been posted!

The Musella Foundation’s proposal is now available for everyone to read. I’d love to hear what you think—what you like, what concerns you have, and how we could improve it.

Read our comment here:
https://t.co/0RS6drONKz
Please share your thoughts in the comments below or message me directly. Your feedback matters!

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

I started finding more long-term survivors.

This was probably the biggest change in my thinking.@ThomasOwenMcCa1 wasn’t alone.

Brad Silver received DCVax-L in one of the earliest trials after being diagnosed with GBM in his early 30s. He’s now a 23-year survivor.

Jamil Newirth was diagnosed at 32 and given approximately 17 months to live. He received UCLA’s personalized dendritic-cell vaccine and was profiled by UCLA more than a decade later, alive and thriving.

Sarah Rigby was diagnosed with GBM in 2011 and has been documented more than 15 years later as a long-term DCVax patient.

Nigel French was diagnosed with GBM in 2015, entered the DCVax-L trial at King’s College Hospital and was subsequently documented in long-term remission.

Kat Charles was diagnosed with grade 4 GBM in 2013 and at one point was told she had only three months to live. She later obtained a personalized dendritic-cell vaccine and continued receiving maintenance booster injections. More than a decade later, hers remains an extraordinary long-term-survivor story.

And I found other early UCLA dendritic-cell-vaccine survivors, including Jennifer Sugioka, Elijah Luyten and Gallia Kistler.

Suddenly Thomas didn’t look like one isolated anomaly anymore.

I was finding a group of people who had received this type of dendritic-cell vaccine and experienced extraordinary survival — 10 years, 12 years, 20-plus years — including patients with many years without recurrence.

And there is something especially important about these early survivors:

Many of them didn’t receive Hiltonol.

Some were treated years before the later UCLA study combining dendritic-cell vaccination with poly-ICLC.

In other words, the extraordinary long-term survivors already existed before these newer combinations were being used.

And that made the newer research even more exciting to me.

If some patients became 10-, 15- and even 20-plus-year survivors with the earlier vaccine approaches, what might be possible if researchers can now strengthen that immune response even further?

That’s the question that gives me hope.

Then came Marnix Bosch’s July 3, 2026 presentation.

At the British Neuro-Oncology Society meeting, Bosch presented new analyses using individual-patient data that hadn’t been available for the original Phase III analysis.

Researchers were now able to match DCVax patients much more precisely with patients from three randomized GBM trials based on important prognostic characteristics.

Across several propensity-score-matching approaches, the estimated survival advantage associated with DCVax-L was 3.4 to 6.3 months, rather than the original 2.8 months. Other statistical approaches produced similar results.

Their overall conclusion was that the original analysis had likely underestimated the survival benefit associated with DCVax-L.

Was that encouraging to me?

Absolutely.

But I want to be honest: an extra handful of months still isn’t what gives me hope.

Whether the median advantage is three months or six months, I don’t want six extra months for my daughter.

I want her to live a long, full life.

What the newer analysis did was strengthen my confidence that DCVax has a real treatment effect and that its original benefit may have been underestimated.

But my hope comes from the long tail.

At five years, 13% of newly diagnosed GBM patients receiving DCVax were alive compared with 5.7% of the external controls — more than double.

And now I know of some of the people represented by that tail.

Brad.

Thomas.

Jamil.

Sarah.

Nigel.

Kat.

Jennifer.

Elijah.

Gallia.

Those are the people I think about.

[rj @sharpie510]

MimiVax CEO Michael Ciesielski interview on failed SurVaxM trial.

https://t.co/dltmMIxtWb

https://t.co/ixI54moshq

#gbm #glioblastoma #dcvax $nwbo

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

[🇩🇰 The Danish Dude 🇬🇱 @FlemmingBruce]

$NWBO

The state of our nearest competitors.

mRNA is a dead horse.

David Reardon and Antonio Chiocca from Dana-Farber working on Mimivax, wrote DCVax-L had failed in this article:

https://t.co/bTAxReM03C

They were clearly wrong, as some of us knew then and everyone know now.

Read comments from then on their hallucinations:

https://t.co/5FRjkSB7Ok

[rj @sharpie510]

$NWBO confirmation:

https://t.co/gc8UXrx0mr

[rj @sharpie510]

Joanna Stanson has left Roswell Park and it sounds like she's heading for a new role at Northwest Biotherapeutics to work on the DCVax Platform.

💪💪💪💪💪💪

#glioblastoma #dcvax $nwbo

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

https://t.co/8Xe6XJPLTI

[Cheesehammer @Cheesehammer11]

$nwbo. They just brought up dcvax and Braelyn on Fox business. Stephen Moore.

[🇩🇰 The Danish Dude 🇬🇱 @FlemmingBruce]

$NWBO

Read about a couple of interesting "participators" in the August CHM, one with relations to earlier manufactoring of DCVax-L.

https://t.co/qlGOYPiOuY

[SemperFITrader @SouthernDrive21]

$NWBO
I had AI go through all my CHM Meeting files from 2023-2026 looking for comparisons of this statement in every CHM meeting file "The Commission advised that the concerns had not been adequately addressed and the applicants should be invited to address these concerns in oral representations to
the Commission." Attached are my findings , had 2 oral request in 2023, 5 in 2024, 2 in 2025 and ours in 2026. This information is the best I could come with with based on what CHM meetings release to the public and trying to piece together what was approved afterwards.

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

🇺🇸❤️ WE MET PRESIDENT TRUMP TONIGHT! ❤️🇺🇸

What an extraordinary evening for our family!

Tonight, Braelyn, Ben, and I had the incredible opportunity to meet President Trump at the rally in Pendleton, South Carolina!

We had only about 20–30 seconds with him, and I knew I needed to make every second count.

I introduced him to Braelyn and thanked him for telling Dr. Oz about her brain cancer story.

I explained that Braelyn had been diagnosed with glioblastoma, the deadliest type of brain tumor, but that today she is CANCER-FREE after receiving DCVax-L, a personalized cancer vaccine developed right here in America!

Yet we must travel all the way to England for her ongoing treatments because we cannot access it here in the United States.

Then something pretty cool happened!

President Trump turned to one of his staffers and instructed them to get me in touch with Dr. Oz!

I also expressed my hope that we could connect with Secretary Kennedy.

As our brief time together came to an end, I made one final appeal:

“Please help bring this American-made treatment back home to America.”

President Trump was incredibly gracious to our family and very kind to Braelyn. We are so grateful for the opportunity to speak with him!

Earlier in the evening, I was also able to give a member of his staff a detailed packet about Braelyn’s journey, DCVax-L, and the obstacles American patients face in accessing promising investigational treatments.

Now we are praying that the connection with Dr. Oz comes through!

Three years ago, Braelyn was given just months to live. Today, she’s 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE RECURRENCE!

Tonight, we had the opportunity to bring her story directly to the President of the United States. ❤️

My prayer is that this opens the door to a much bigger conversation—one that could change the future for countless American cancer patients.

📸 We were not permitted to bring our phones into the private meeting with President Trump, so we couldn’t take our own pictures with him. His staff took an official photograph of us together, which we’re told will be emailed to us. I can’t wait to share it! In the meantime, here are some pictures from our unforgettable evening.

Thank you to EVERYONE who helped make tonight possible and to all of you who continue to share Braelyn’s story. You helped us get this far, and we’re not stopping now! ❤️🙏

@realDonaldTrump @DrOzCMS @WhiteHouse

#DCVaxForBraelyn #DCVax

[rj @sharpie510]

#gbm #glioblastoma #dcvax $nwbo

BeProactive
FreezeYourTumor
GetDCVax
QualityOfLifeMatters

https://t.co/X9PZLFwvx1

[rj @sharpie510]

#GBM #Glioblastoma

Multiparametric MRI can be used to predict pseudo-progression. A 63yo lived 61 months on one course of $nwbo #DCVax-L, but did not access a new (second) batch, unlike Sarah Rigby, who did, and is still thriving cancer-free ~15 years.
🙏
https://t.co/A6fLAmQEYz

[Al Musella @AlMusella]

Fantastic start. One of my friends is doing great with this and avoided surgery and radiation. Major step forward.

Now do more! Consider dc-vax For glioblastoma. Phase 3 trial looked very good but was criticized for the way the external control group didn’t have patient level data. But the analysts was recently redone with patient level data which made the results look even better.